, Question 1
Under the Wyoming Pharmacy Act, which action best illustrates the Board's
authority when a licensee's conduct violates both a Board rule and a federal
statute?
A. The Board must defer entirely to federal enforcement and cannot act.
B. The Board may independently discipline for the rule violation, even if
federal charges are pending.
C. The Board loses jurisdiction once a federal investigation begins.
D. The Board may only issue a warning until federal disposition.
Correct Answer: B - The Board may independently discipline for
the rule violation, even if federal charges are pending.
RATIONALE
State boards retain independent police power to discipline licensees
for violations of state practice acts and rules, regardless of parallel
federal proceedings. Deferral is not required, and jurisdiction is not
automatically lost. Options A, C, and D incorrectly limit the Board's
authority.
Question 2
A pharmacy dispenses a Schedule II controlled substance pursuant to a verbal
order. Which condition must be satisfied for this to be lawful under Wyoming
law and DEA rules?
A. The pharmacist must personally know the prescriber.
B. The quantity prescribed must not exceed a 72-hour supply.
C. The prescriber must provide a written follow-up prescription within 7
days.
D. The pharmacist must obtain PDMP consent from the patient.
Correct Answer: C - The prescriber must provide a written
follow-up prescription within 7 days.
Page 2
, RATIONALE
DEA and Wyoming law allow oral Schedule II prescriptions only in
genuine emergencies, with a written follow-up within 7 days. Personal
acquaintance, a 72-hour supply cap, and PDMP consent are not
statutory prerequisites for the emergency exception. The 7-day written
follow-up is the key compliance element.
Question 3
Which scenario most accurately reflects a mandatory PDMP query requirement
in Wyoming?
A. Querying only when dispensing a Schedule II opioid.
B. Querying before dispensing any controlled substance, with limited
exceptions.
C. Querying only for new patients.
D. Querying only if the patient requests it.
Correct Answer: B - Querying before dispensing any controlled
substance, with limited exceptions.
RATIONALE
Wyoming mandates PDMP review prior to dispensing controlled
substances, subject to specific statutory exceptions (e.g., certain
settings). Restricting queries to Schedule II opioids, new patients, or
patient request under-implements the law. Option B captures the broad
mandatory query duty.
Question 4
A pharmacist and physician enter a collaborative practice agreement. Which
element is most critical for legal validity under Wyoming law?
A. The agreement must be approved by the Board of Medicine only.
B. The agreement must be in writing, define scope, and comply with
Board rules.
C. The agreement must be filed with the DEA.
Page 3
, D. The agreement must be limited to non-controlled substances.
Correct Answer: B - The agreement must be in writing, define
scope, and comply with Board rules.
RATIONALE
Wyoming collaborative practice requires a written agreement that
defines the pharmacist's scope and meets Board requirements.
Approval by only one board, DEA filing, or a non-controlled
limitation is not the core statutory requirement. Option B reflects the
essential legal elements.
Question 5
Which change is most consistent with SF 121 updates to Wyoming pharmacy
law?
A. Elimination of pharmacist immunization authority.
B. Expansion of pharmacist prescribing under defined protocols.
C. Prohibition of telepharmacy.
D. Removal of PDMP requirements.
Correct Answer: B - Expansion of pharmacist prescribing under
defined protocols.
RATIONALE
SF 121 expands pharmacist scope, including prescribing under
protocols, aligning with modern collaborative care models. It does not
eliminate immunization, ban telepharmacy, or remove PDMP duties.
Option B reflects the expansionary intent of the legislation.
Question 6
A pharmacy's DEA registration is suspended. Which activity may the
pharmacy lawfully continue?
A. Dispensing controlled substances for maintenance patients.
B. Dispensing non-controlled substances.
Page 4
Under the Wyoming Pharmacy Act, which action best illustrates the Board's
authority when a licensee's conduct violates both a Board rule and a federal
statute?
A. The Board must defer entirely to federal enforcement and cannot act.
B. The Board may independently discipline for the rule violation, even if
federal charges are pending.
C. The Board loses jurisdiction once a federal investigation begins.
D. The Board may only issue a warning until federal disposition.
Correct Answer: B - The Board may independently discipline for
the rule violation, even if federal charges are pending.
RATIONALE
State boards retain independent police power to discipline licensees
for violations of state practice acts and rules, regardless of parallel
federal proceedings. Deferral is not required, and jurisdiction is not
automatically lost. Options A, C, and D incorrectly limit the Board's
authority.
Question 2
A pharmacy dispenses a Schedule II controlled substance pursuant to a verbal
order. Which condition must be satisfied for this to be lawful under Wyoming
law and DEA rules?
A. The pharmacist must personally know the prescriber.
B. The quantity prescribed must not exceed a 72-hour supply.
C. The prescriber must provide a written follow-up prescription within 7
days.
D. The pharmacist must obtain PDMP consent from the patient.
Correct Answer: C - The prescriber must provide a written
follow-up prescription within 7 days.
Page 2
, RATIONALE
DEA and Wyoming law allow oral Schedule II prescriptions only in
genuine emergencies, with a written follow-up within 7 days. Personal
acquaintance, a 72-hour supply cap, and PDMP consent are not
statutory prerequisites for the emergency exception. The 7-day written
follow-up is the key compliance element.
Question 3
Which scenario most accurately reflects a mandatory PDMP query requirement
in Wyoming?
A. Querying only when dispensing a Schedule II opioid.
B. Querying before dispensing any controlled substance, with limited
exceptions.
C. Querying only for new patients.
D. Querying only if the patient requests it.
Correct Answer: B - Querying before dispensing any controlled
substance, with limited exceptions.
RATIONALE
Wyoming mandates PDMP review prior to dispensing controlled
substances, subject to specific statutory exceptions (e.g., certain
settings). Restricting queries to Schedule II opioids, new patients, or
patient request under-implements the law. Option B captures the broad
mandatory query duty.
Question 4
A pharmacist and physician enter a collaborative practice agreement. Which
element is most critical for legal validity under Wyoming law?
A. The agreement must be approved by the Board of Medicine only.
B. The agreement must be in writing, define scope, and comply with
Board rules.
C. The agreement must be filed with the DEA.
Page 3
, D. The agreement must be limited to non-controlled substances.
Correct Answer: B - The agreement must be in writing, define
scope, and comply with Board rules.
RATIONALE
Wyoming collaborative practice requires a written agreement that
defines the pharmacist's scope and meets Board requirements.
Approval by only one board, DEA filing, or a non-controlled
limitation is not the core statutory requirement. Option B reflects the
essential legal elements.
Question 5
Which change is most consistent with SF 121 updates to Wyoming pharmacy
law?
A. Elimination of pharmacist immunization authority.
B. Expansion of pharmacist prescribing under defined protocols.
C. Prohibition of telepharmacy.
D. Removal of PDMP requirements.
Correct Answer: B - Expansion of pharmacist prescribing under
defined protocols.
RATIONALE
SF 121 expands pharmacist scope, including prescribing under
protocols, aligning with modern collaborative care models. It does not
eliminate immunization, ban telepharmacy, or remove PDMP duties.
Option B reflects the expansionary intent of the legislation.
Question 6
A pharmacy's DEA registration is suspended. Which activity may the
pharmacy lawfully continue?
A. Dispensing controlled substances for maintenance patients.
B. Dispensing non-controlled substances.
Page 4
